Notably, after lenvatinib treatment of HCC cells, knockdown of the FGFR4 gene, and FGF19 stimulation, the mRNA levels of FGFR but not PD-L1 were affected [24]. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.